NEW YORK (GenomeWeb) – OpGen announced today that the New York State Department of Health has approved its Acuitas MDRO Gene Test for use by doctors and healthcare providers in the state.

Acuitas provides information on the presence of 10 MDRO resistance genes in a single sample from a patient. Approval of OpGen's CLIA laboratory to perform testing in New York includes approval for the complete OpGen MDRO testing workflow, including gene testing on perianal swabs and clinical isolates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.